SRT2183 (C007B-272627)

InformationSRT2183 is a small-molecule activator of the sirtuin subtypeSIRT1, currently being developed by Sirtris Pharmaceuticals.TargetsSIRT1In vitroSRT2183 is potent with growth arrest and apoptosis induced at doses ranging from 1-20 μM. SRT2183 treatment leads to increased mRNA levels of pro-apoptosis, growth arrest, and DNA damage response genes. SRT1720, SRT2183, SRT1460, and resveratrol exhibit multiple off-target activities against receptors, enzymes, transporters, and ion channels. They are not direct activators of SIRT1. SRT2183 has little or no effect on SIRT1 deacetylating activity with native full-length substrates. SRT2183 activates AMPK, increases Sirt1 expression and decreases RelA/p65 lysine310 acetylation, critical for NF-κB activation, and an established Sirt1 target and inhibits RANKL-induced osteoclast generation and resorptive capacity in bone marrow macrophages.Cell Research(from reference)Cell lines：Bone-marrow derived macrophages(BMMs) Concentrations：1μM Incubation Time：72 h.

Specifications and Purity: ≥99%

Molecular Formula: C27H24N4O2S

Molecular Weight: 468.57

PubChem CID: 24180126

Isomeric SMILES: C1CN(C[C@@H]1O)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6C=C5

Related Documents: https://aladdin-for-icloud-store.oss-cn-hangzhou.aliyuncs.com/aladdinsci/pdp/sds/1/S413956-SCI_4db3d9caa8822d40e40466d4ba673449.pdf